|
|
Volumn 40, Issue 2, 1997, Pages 141-158
|
|
Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACETYLSALICYLIC ACID;
ANGIOPEPTIN;
ANTICOAGULANT AGENT;
ANTILIPEMIC AGENT;
ANTITHROMBOCYTIC AGENT;
CALCIUM CHANNEL BLOCKING AGENT;
CILAZAPRIL;
CIPROSTENE;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
DIPYRIDAMOLE;
ENOXAPARIN;
FIBRINOGEN RECEPTOR ANTAGONIST;
HEPARIN;
HIRUDIN;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
METHYLPREDNISOLONE;
MEVINOLIN;
NADROPARIN;
NITRIC OXIDE;
OMEGA 3 FATTY ACID;
PLACEBO;
PRAVASTATIN;
TICLOPIDINE;
TRANILAST;
TRAPIDIL;
VAPIPROST;
ANGIOCARDIOGRAPHY;
ANGIOPLASTY;
ANIMAL MODEL;
BLEEDING;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
CORONARY ARTERY BYPASS GRAFT;
CORONARY ARTERY DISEASE;
DOSE RESPONSE;
EXPERIMENTAL MODEL;
HUMAN;
HYPERLIPIDEMIA;
INTRAVENOUS DRUG ADMINISTRATION;
MAJOR CLINICAL STUDY;
MULTICENTER STUDY;
NONHUMAN;
RANDOMIZED CONTROLLED TRIAL;
RESTENOSIS;
REVIEW;
SUBCUTANEOUS DRUG ADMINISTRATION;
TRANSLUMINAL CORONARY ANGIOPLASTY;
TREATMENT OUTCOME;
|
|
EID: 0030885557
PISSN: 00330620
EISSN: None
Source Type: Journal
DOI: 10.1016/S0033-0620(97)80006-0 Document Type: Article |
|
Times cited : (92)
|
|
References (183)
|
